Cargando…

Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study

BACKGROUND: Causative treatment of patients with wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is lacking. Recent reports indicate the potential use of epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, to inhibit amyloid fibril formation. We sought to investiga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siepen, Fabian aus dem, Bauer, Ralf, Aurich, Matthias, Buss, Sebastian J, Steen, Henning, Altland, Klaus, Katus, Hugo A, Kristen, Arnt V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675646/ https://www.ncbi.nlm.nih.gov/pubmed/26673202 http://dx.doi.org/10.2147/DDDT.S96893

Ejemplares similares

Wild-type transthyretin amyloidosis in female patients
por: Kristen, Arnt V, et al.
Publicado: (2015)

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report
por: Kristen, Arnt V., et al.
Publicado: (2012)

Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis
por: Hein, Selina J, et al.
Publicado: (2021)

T1 mapping: useful for treatment monitoring in patients with senile systemic amyloidosis?
por: dem Siepen, Fabian aus, et al.
Publicado: (2014)

Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
por: Hein, Selina, et al.
Publicado: (2021)

Comparison of late gadolinium enhancement patterns in different forms of cardiac amyloidosis
por: Kammerer, Rebekka, et al.
Publicado: (2013)

Thickness of the midventricular left ventricular wall is predictive of survival in different forms of cardiac amyloidosis
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Non-invasive risk stratification of patients with TTR amyloidosis
por: Scherer, Katrin A, et al.
Publicado: (2013)

Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis
por: Arenja, Nisha, et al.
Publicado: (2019)

MRI detected mass decrease in patients with amyloidosis after treatment with green tea: a one year follow-up study
por: Buss, Sebastian, et al.
Publicado: (2012)

Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms
por: Korosoglou, Grigorios, et al.
Publicado: (2021)

Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy
por: Aurich, Matthias, et al.
Publicado: (2023)

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
por: Dittrich, Tobias, et al.
Publicado: (2019)

Extracellular volume assessed by CMR T1-mapping correlates with histologically determined amount of diffuse fibrosis in DCM
por: aus dem Siepen, Fabian, et al.
Publicado: (2014)

Non-invasive measurement of myocardial extracellular volume using T1 mapping as a novel biomarker of diffuse fibrosis in dilated cardiomyopathy
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis
por: Ochs, Marco M., et al.
Publicado: (2017)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Diffuse myocardial fibrosis in early forms of dilated cardiomyopathy: insights from T1 mapping cardiovascular magnetic resonance
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Assessment of myocardial strain in patients with myocarditis by cardiac magnetic resonance imaging
por: Andre, Florian, et al.
Publicado: (2014)

Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis
por: Hoerbrand, Isabel A., et al.
Publicado: (2022)

Standardized assessment of global longitudinal and circumferential strain - a modality independent software approach
por: Riffel, Johannes, et al.
Publicado: (2015)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Cardiac magnetic resonance strain imaging in systemic light chain amyloidosis
por: Andre, Florian, et al.
Publicado: (2014)

Variability of cardiovascular magnetic resonance (CMR) T1 mapping parameters in healthy volunteers during long-term follow-up
por: aus dem Siepen, Fabian, et al.
Publicado: (2018)

Right ventricular function in dilated cardiomyopathy: relation to location of focal myocardial fibrosis
por: Abdelrazek, Mohamed A, et al.
Publicado: (2013)

Feasibility of high dose dobutamine stress and scar imaging in high field open MRI in patients with suspected coronary artery disease
por: Petry, Phillip G, et al.
Publicado: (2013)

Negative bone scintigraphy in wild-type transthyretin cardiac amyloidosis
por: Martini, Nicolò, et al.
Publicado: (2020)

Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg
por: Broussier, Amaury, et al.
Publicado: (2021)

Wild-Type Transthyretin Cardiac Amyloidosis in a Transplanted Heart
por: Stern, Lily K., et al.
Publicado: (2023)

Incidence and predictors of worsening heart failure in patients with wild‐type transthyretin cardiac amyloidosis
por: Ladefoged, Bertil Thyrsted, et al.
Publicado: (2022)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Identification of wild‐type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS)
por: Ladefoged, Bertil, et al.
Publicado: (2022)

With M-protein positive, could transthyretin amyloidosis be easily excluded? Not necessarily! Wild-type transthyretin amyloidosis with Waldenström’s macroglobulinaemia: a case report
por: Kinoshita, Haruyuki, et al.
Publicado: (2022)

A case of wild-type transthyretin amyloidosis associated with organizing pneumonia
por: Nakao, Makoto, et al.
Publicado: (2017)

Wild-Type Transthyretin Amyloidosis in Female Patients　― Consideration of Sex Differences ―
por: Ochi, Yuri, et al.
Publicado: (2021)

Prognostic value of exercise echocardiography in patients with wild-type transthyretin amyloidosis
por: Agudo, Cristina Aguilera, et al.
Publicado: (2022)

Multimodality assessments of wild‐type transthyretin cardiac amyloidosis with no ventricular hypertrophy
por: Iwaya, Takuma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fslqosvnvrtl9a112bnc0mbhss